


TREATMENT PROTOCOL USING DOXERCALCIFEROL (HECTOROL®) AND INTACT PTH AND THE CAP/CIP RATIO

Richard Amerling. Beth Israel Med. Ctr., New York, NY, USA.

The 1-84 PTH/7-84 PTH (CAP/CIP) ratio has been demonstrated in two histology studies to be the best indicator of bone turnover status. Tokumoto has determined that the ESRD patients with a ratio of less than 1.4 have adynamic bone disease. K/DO Q I suggests that patients with an intact PTH value of less than 100 pgm/ml have adynamic bone disease and that 150-300 pgm/ml is the target range for dialysis patients. It is important to administer a small dose of vitamin D to ESRD patients to compensate for the loss of the kidney as a source of active vitamin D. We have incorporated these considerations into a treatment protocol with the use of doxercalciferol (Hectorol®).

The Total Intact PTH and CAP/CIP Ratio Treatment Guideline Using Hectorol (Doxercalciferol)



* Provided that the serum calcium is <10.2 mg/dL and the Calcium x Phosphate product is <55. If serum calcium is >10.2 mg/dL or Calcium x Phosphate product is >55 - reduce dose by 50%. Doses are IV 3X/week.

Monthly PTH measurements until PTH values and dosing changes have stabilized

Amerling R. Treatment Protocol using Doxercalciferol (Hectorol®) and Intact PTH and the CAP/CIP Ratio. *Am J Kidney Dis* 2004(April); 43(4):8, pp. A16.